An unprecedented surge in national planning has swept the world in the fight against antimicrobial resistance (AMR), yet the World Health Organization (WHO) warns that “an unfulfilled plan helps no one.” Newly released data ahead of World AMR Awareness Week reveal that while 173 countries have now reported developing action plans—more than double the count just seven years ago—the majority are falling short in actually delivering protection to their populations.

The latest WHO Tracking Antimicrobial Resistance Country Self-assessment Survey (TrACSS) paints a stark picture: Only 22% of nations report having both secured funding and achieved full implementation of national AMR plans. This means billions remain exposed to risks. Serious deficiencies persist along the healthcare chain, from infection prevention to diagnosis and treatment. “Common infections become harder to treat, and routine procedures, including surgery, childbirth, and cancer care, become riskier” as drugs grow less effective, the WHO cautioned in its official findings.

Testing Capacity: A Fractured First Line of Defense

Diagnostic shortfalls undermine the global response. Just 36% of countries indicated their national reference laboratories are equipped to test prioritized bacteria and fungi—a figure less than half the goal set for 2030. This lack of capacity means resistant infections often go undetected while patients risk being prescribed costly or ineffective antibiotics. Without robust surveillance, local trends in resistance escape notice, foiling efforts to target interventions and contain outbreaks.

Guidance for appropriate antibiotic use is far from universal: only 63% of nations have developed such guidelines, and just over half can systematically monitor antibiotic usage and resistance trends. This fragmented infrastructure not only skews understanding of where dangerous resistance is appearing, but also enables the misuse and overuse of antimicrobials—the very breeding ground for “superbugs.” The steady climb of resistance is evident in 2023 statistics: globally, approximately one in six bacterial infections confirmed in laboratories proved resistant to antibiotics.

Inequity in Preparedness: Low-Income Countries Left Behind

The gap between strategy and real-world protection is especially pronounced for lower-income regions. According to WHO AMR Secretariat Director Dr. Marc Sprenger, only about 30% of low-income countries have any national AMR plan underway. These nations, where infectious disease is more widespread and health systems more fragile, are likely to suffer the greatest impact as first-line drugs lose effectiveness. Yet they struggle to marshal the expertise and resources needed to build laboratory networks, surveillance, and coordinated responses across human, animal, and environmental sectors.

While the “One Health” approach—involving health, agriculture, and environmental leaders—has gained traction, actual progress beyond rhetoric is limited by gross funding shortfalls and competing national priorities. The risk is not confined by borders: microbes travel, and resistant pathogens threaten to upend medical progress everywhere by endangering surgery, childbirth, cancer therapy, and more.

Glimmers of Progress Amid Persistent Risks

A handful of recent advances illustrate what is possible when policy translates into action. The WHO, along with global health partners, released two new tools in 2026 to aid laboratories in the diagnosis of bacterial and fungal infections. In the fight against the most notorious superbugs, such as drug-resistant gonorrhoea, international surveillance networks (like the Enhanced Gonococcal Antimicrobial Surveillance Programme, EGASP) have led to informed guideline revisions and the development of new antibiotics, such as Zoliflodacin—a novel drug recently found to be as effective as current therapies in combatting gonorrhoea.

Yet these successes remain exceptions rather than rules. With over 90% of the world’s population living in a country with some form of AMR plan on paper, the contrast with on-the-ground weakness in testing, regulation, and infection control remains sharp. The WHO has called on national governments and global development partners to “implement plans with investments in infection prevention, surveillance, equitable access to essential antimicrobials and quality diagnostics” without delay.

As World AMR Awareness Week urges shared action under the theme “One Health, one action: Prevent AMR now,” the warning from global health leaders is clear: unless plans are transformed into funded, coordinated initiatives, the world risks squandering its hard-won medicines and undermining the safety of medical care for generations. The pressing unanswered question remains—will countries bridge the gap between promise and protection before superbugs outpace every available antibiotic?

Reporting sources